- Why Biological Actives Need More Than Standard Formulation
- What Microencapsulation Does in a Biopesticide Context
- Incapsulex®: Bionema's Microencapsulation Platform
- The Commercial Significance of Formulation Technology in Biological Crop Protection
- Where Incapsulex® Fits in the Broader Bionema Platform
- Who This Technology Is Relevant For
- The Gap Between Good Science and Repeatable Field Performance
- FAQs
Biological actives are, by nature, fragile. A fungal spore that performs reliably in a controlled laboratory environment can lose viability within hours of field application if exposed to UV radiation, temperature swings, or desiccation. An entomopathogenic organism that demonstrates strong efficacy in a petri dish may never reach its target pest in sufficient numbers if the formulation fails to adhere, spread, or release at the right moment.
That gap between laboratory performance and repeatable field results is one of the most persistent technical problems in biopesticide development. Microencapsulation is the formulation mechanism designed to close it — and in biological crop protection, how that encapsulation is engineered matters enormously.
This article explains how microencapsulation works in practice, why it matters more for biological actives than for conventional chemistry, and how Bionema's proprietary Incapsulex® platform addresses these challenges — with direct relevance to technical evaluators, formulation directors, and commercial partners assessing biopesticide delivery technology.
Why Biological Actives Need More Than Standard Formulation
Conventional synthetic pesticides are chemically stable molecules. They can tolerate a degree of environmental exposure without losing function. Biological actives — whether fungal spores, bacterial cells, entomopathogenic organisms, or natural compounds — do not share that tolerance.
The specific challenges include:
- UV degradation: Solar radiation is one of the fastest routes to viability loss for fungal and bacterial actives applied to leaf surfaces or soil
- Temperature sensitivity: Thermal stress during storage, transit, and application can compromise cell integrity and germination rates
- Desiccation: Moisture loss after application, particularly on exposed foliage or dry soil surfaces, accelerates mortality in microbial actives
- Oxidation: Exposure to oxygen can degrade sensitive biological compounds before they reach the target site
- Premature release: Without a controlled release mechanism, an active may dissipate before pest pressure peaks or before the target organism reaches the developmental stage where it is most susceptible
Standard wettable powder or suspension concentrate formulations offer limited protection against these stressors. They may keep a product shelf-stable, but provide little defence once the active is exposed to field conditions.
This is where microencapsulation becomes a technically meaningful intervention — not a cosmetic formulation step.
What Microencapsulation Does in a Biopesticide Context
Microencapsulation is the process of surrounding a biological active — or a group of actives — within a protective shell or matrix at the microscale. The shell controls what gets in and what gets out, and when.
In biopesticide formulation, a well-designed microcapsule serves several practical functions.
Protection from environmental stressors. The capsule wall acts as a physical barrier against UV radiation, oxygen, and moisture fluctuation. A fungal spore enclosed within a stable matrix is substantially less exposed to the conditions that would otherwise degrade it between application and germination.
Controlled release. Rather than releasing the active immediately upon application, a microencapsulated formulation can be engineered to respond to specific triggers — moisture, pH shift, temperature change, or mechanical disruption by a target pest. This extends the active window and improves timing alignment with pest susceptibility.
Stability through the supply chain. The same protective properties that matter in the field also matter before the product reaches the grower. A formulation that degrades on the shelf is commercially useless regardless of its laboratory performance.
Improved handling and compatibility. Encapsulation can reduce the reactivity of a biological active with adjuvants, carrier solutions, or other tank mix components, supporting broader application flexibility.
The engineering challenge is real. The capsule must be robust enough to protect the active under stress, but must also release it at the right time, in the right location, and in a form that retains biological function. Getting that balance wrong in either direction — too protective or too permeable — produces a formulation that fails in the field for different reasons.
Incapsulex®: Bionema’s Microencapsulation Platform
Incapsulex® is Bionema's proprietary microencapsulation platform, developed specifically for the protection, stability, and controlled release of biological actives. It is one of three core formulation and delivery platforms at the centre of Bionema's technology offering, alongside Adhesulex® (spreading, adhesion, and target delivery) and BiofilmTech® (root-zone microbial persistence).
The platform is designed to address the specific vulnerabilities of biological actives across the full product lifecycle — from manufacture through storage, transit, application, and post-application performance in the field.
Incapsulex® underpins several of Bionema's commercial products and is available as a licensable or co-developable technology for companies developing their own biological crop protection formulations.
What Makes the Platform Technically Distinct
The commercial case for Incapsulex® rests on specific technical properties that matter to formulation directors and product developers evaluating encapsulation options.
Active-specific engineering. Incapsulex® is not a one-size-fits-all capsule format. The platform is adapted to the specific biological active being protected — accounting for its size, surface chemistry, moisture requirements, and release conditions. This matters because a fungal spore and a bacterial cell have different encapsulation requirements, and a platform that treats them identically will underperform with at least one.
UV and thermal protection. The platform provides documented protection against UV degradation and thermal stress — two of the primary causes of viability loss in field-applied biological actives. This extends the effective application window and supports performance under variable weather conditions.
Controlled release architecture. Incapsulex® supports formulation designs where release is triggered by environmental or biological cues rather than immediate exposure. This is particularly relevant for soil-applied or foliar-applied products where timing the release to coincide with pest activity or crop growth stage is commercially important.
Compatibility with downstream delivery. Because Incapsulex® is developed within the same platform architecture as Adhesulex®, encapsulated actives can be formulated to benefit from both capsule-level protection and targeted delivery at the point of application. These two platforms are designed to work together, not as independent modules.
The Commercial Significance of Formulation Technology in Biological Crop Protection
Formulation is often treated as a downstream step in biological product development — something that follows the discovery and efficacy work. In practice, formulation quality is frequently the deciding factor in whether a biological product achieves commercial scale.
A biological active with strong efficacy data that cannot be stabilised for a 12-to-24-month shelf life is not commercially viable. A product that performs well in controlled trials but degrades unpredictably under field conditions will not build the grower confidence needed for repeat purchase. A formulation that cannot be manufactured consistently at scale will not survive the transition from development to commercial supply.
These are not hypothetical risks. They are among the most common reasons that biologically active compounds with genuine efficacy potential fail to reach or sustain commercial markets.
Microencapsulation technology like Incapsulex® addresses these failure modes directly. For technology and licensing partners evaluating biological formulation platforms, the relevant question is not just whether the encapsulation works in a laboratory setting, but whether it has been demonstrated in products that have met Tier-1 commercial evaluation standards.
In 2021, Syngenta Crop Protection acquired two Bionema products and supporting technology. That transaction is documented evidence that Bionema's formulation and delivery technology met the technical and commercial evaluation criteria of one of the largest crop protection companies in the world — and it remains the most concrete external validation available for the quality of the underlying platform work.
Where Incapsulex® Fits in the Broader Bionema Platform
Incapsulex® does not operate in isolation. Bionema's approach to biological crop protection is built around the integration of multiple platform capabilities, each addressing a different point of failure in the journey from active ingredient to field performance.
- Incapsulex® protects the active and controls its release
- Adhesulex® ensures the formulation reaches and adheres to the target surface
- BiofilmTech® supports root-zone microbial persistence and rhizosphere activity for soil-applied biologicals
Together, these platforms mean a biological active developed or licensed through Bionema can be engineered for performance at each stage: protection, delivery, and persistence. For a formulation director or external innovation lead evaluating biological delivery technology, this integrated approach reduces the number of separate technology relationships needed to bring a product from active to field.
Bionema also holds the King's Award for Enterprise: Innovation 2024 and the King's Award for Enterprise: Sustainable Development 2026 — recognition that reflects both the technical quality and the sustainability credentials of the platform approach.
Who This Technology Is Relevant For
Incapsulex® and the broader Bionema formulation platform are relevant to three groups of technical and commercial buyers.
Formulation and R&D directors at biological product companies developing new biopesticide products who need microencapsulation capability without building it in-house. Licensing or co-developing Incapsulex® provides access to a tested platform with documented Tier-1 validation.
Portfolio and business development leads at agrochemical companies expanding into biologicals in response to EU and UK regulatory withdrawal of chemical actives. The Europe biopesticides market is growing at 9.97 percent CAGR through 2031, and the global biologicals market reached USD 2 billion in 2024. Companies entering or scaling in this space need formulation infrastructure that delivers consistent field performance — not just laboratory efficacy.
Distribution and commercial partners building biologicals product lines who need products with credible, stable formulations that growers can rely on across variable application conditions.
For professional end users — agronomists, growers, and turf managers — the practical implication is more straightforward: products formulated with Incapsulex® are designed to maintain viability from manufacture through to the point of action in the field, reducing the performance variability that has historically made some biological products difficult to recommend with confidence.
The Gap Between Good Science and Repeatable Field Performance
The biologicals sector has no shortage of promising actives. What it has historically lacked is the formulation infrastructure to turn those actives into products that perform consistently enough to displace conventional chemistry in commercial IPM programmes.
Microencapsulation is not a complete solution to that problem, but it addresses one of its most technically tractable components. Protecting a biological active from the moment it leaves the manufacturing facility to the moment it needs to act in the field is an engineering problem — and engineering problems have engineering solutions.
Incapsulex® is Bionema's answer to that problem, developed from a Swansea University research foundation and validated through commercial product development across agriculture, horticulture, turf and amenity, forestry, and public health.
For companies evaluating biological formulation technology, the combination of a named, proprietary microencapsulation platform, an integrated delivery architecture, and documented Tier-1 technology transfer is a meaningful differentiator in a market where most platform claims remain at the conceptual level.
To learn more about Incapsulex® and Bionema's formulation technology platforms, visit bionema.com.
FAQs
What is microencapsulation in biological crop protection?
Microencapsulation is a formulation process in which a biological active — such as a fungal spore or bacterial cell — is enclosed within a protective shell or matrix at the microscale. In biological crop protection, this shields the active from UV radiation, temperature stress, and desiccation, and can be engineered to release the active at a controlled rate in response to environmental or biological triggers.
Why is microencapsulation particularly important for biopesticides compared to conventional pesticides?
Biological actives are inherently more sensitive to environmental stress than synthetic chemical molecules. Without protective formulation, fungal spores, bacterial cells, and other biological actives can lose viability rapidly after application. Microencapsulation provides a physical barrier that extends viability, supports shelf stability, and improves the alignment between active release and pest susceptibility windows.
What is Incapsulex® and who developed it?
Incapsulex® is a proprietary microencapsulation platform developed by Bionema, a UK biological crop protection company spun out of Swansea University. It is designed specifically for the protection, stability, and controlled release of biological actives, and forms part of Bionema's broader formulation and delivery technology architecture alongside Adhesulex® and BiofilmTech®.
How does controlled release work in a microencapsulated biopesticide?
In a controlled release formulation, the capsule wall is engineered to break down or become permeable in response to specific triggers — such as moisture, pH change, temperature, or physical disruption. This means the biological active is not immediately exposed upon application but is released at a time and rate designed to coincide with optimal pest control conditions.
Can Incapsulex® technology be licensed or used in co-development?
Yes. Bionema offers licensing, co-development, and technology transfer routes for its formulation platforms, including Incapsulex®. The 2021 Syngenta Crop Protection acquisition of two Bionema products and supporting technology provides documented evidence of the platform's commercial viability at Tier-1 evaluation standards.
What sectors does Incapsulex® technology apply to?
Incapsulex® has been developed and applied across Bionema's full sector coverage, including agriculture, horticulture, turf and amenity, forestry, and public health. The platform is not limited to a single crop or application type.
How does Incapsulex® relate to Bionema's other formulation platforms?
Incapsulex® works alongside Adhesulex®, which handles spreading, adhesion, and target delivery, and BiofilmTech®, which supports root-zone microbial persistence. Together, the three platforms address protection, delivery, and persistence across the biological active's lifecycle from manufacture to field action — designed to function as an integrated system rather than independent tools.
